Novo Nordisk A/S (NVO) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

Recent earnings‑estimate revisions have spurred a rally, indicating analysts are optimistic about Novo’s near‑term earnings growth. This optimism is reinforced by the Singapore label update that added STEP UP trial data, potentially expanding Wegovy’s indications for non‑diabetic patients and broadening prescribing patterns. The label change may lift sales projections in the coming weeks. Meanwhile, Novo’s partnership with Vivani to evaluate a semaglutide implant introduces a new delivery platform that could improve adherence and open a new revenue stream. However, the company’s upcoming earnings guidance projects a 15.46 % decline in EPS and a 2.89 % drop in revenue, which could temper the positive sentiment. Deutsche Bank’s forecast of a single‑digit downside for the Wegovy oral pill through 2026 and double‑digit declines for the injectable version adds further uncertainty to the obesity portfolio. UBS’s overweight rating and the impending Medicare GLP‑1 Bridge Program starting July 1 are near‑term catalysts that could validate demand and influence pricing dynamics. The announced share‑repurchase program signals confidence in the balance sheet and may support earnings per share, but its pace and scale remain to be seen. Traders should monitor the next earnings release for guidance updates, the progress of the STEP UP data integration, the Phase 1 results of the Vivani implant, and the rollout of Medicare coverage to gauge the short‑term trajectory.

NVO|Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NYQ

Country

Denmark

Website

novonordisk.com

Symbol

NVO

Description

Novo Nordisk A/S is a global pharmaceutical company specializing in treatments for diabetes, obesity, and rare diseases. Its core business centers on developing, manufacturing, and distributing a portfolio of medications, including insulin pens, growth hormone pens, and injection needles, catering to diverse patient needs across multiple international markets. The company's value proposition lies in its dedication to innovation, as evidenced by its smart diabetes solutions like smart insulin pens and dose guidance applications, alongside its focus on emerging therapies. Novo Nordisk operates through two primary segments: Diabetes and Obesity Care, and Rare Disease, addressing significant unmet medical needs. Strategic collaborations, such as the agreement with UNICEF, further demonstrate the company's commitment to improving global health outcomes.

NVO|Earnings Snapshot

Earnings Summary

Novo Nordisk A/S is a global pharmaceutical company focused on diabetes, obesity, and rare disease treatments, offering a portfolio that includes smart insulin pens and growth hormone pens, and operating through Diabetes and Obesity Care and Rare Disease segments. In the last four quarters, the company posted a 6.34 EPS in Q4 2024 versus a 6.115 estimate, and 6.53 EPS in Q1 2025 versus a 6.074 estimate, both beating analysts; Q2 2025 saw a 5.96 EPS against a 6.00433 estimate, a miss, while Q3 2025 delivered 4.5 EPS versus a 4.24333 estimate, a beat. Revenue trended downward each quarter, falling from $85.68B in Q4 2024 to $78.09B in Q1 2025, $76.86B in Q2 2025, and $74.98B in Q3 2025, indicating a contraction in top line even as earnings continued to beat expectations in three of the four periods. Historically, Novo has maintained a pattern of EPS beats amid revenue declines, suggesting resilient profitability and effective cost management. Recent news highlights a DKK15 billion share‑repurchase program aimed at B shares, a lift in Wegovy sales prompting a 2026 revenue guidance revision, and a Medicare GLP‑1 Bridge Program that could boost prescription volumes; the partnership with Shantha Biologics to manufacture insulin cartridges in India is expected to cut costs and improve supply‑chain resilience, while Nordea’s upgrade to Buy underscores confidence in the company’s pipeline. Investors should watch the pace of the buyback program, the rollout and reimbursement terms of the Medicare GLP‑1 Bridge Program, and any confirmation of the revised 2026 revenue guidance, as well as the impact of cost savings from the insulin cartridge partnership on near‑term margins.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$6.96	-	-
Q3'25	$4.24	$4.50	+6.0%
Q2'25	$6.00	$5.96	-0.7%
Q1'25	$6.07	$6.53	+7.5%
Q4'24	$6.12	$6.34	+3.7%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$71.6B	-	-
Q3'25	-	$75.0B	-
Q2'25	-	$76.9B	-
Q1'25	-	$78.1B	-
Q4'24	-	$85.7B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

NVO Stock Snapshot

NVO is currently trading at $49.49, giving Novo Nordisk A/S a market cap of 1419.18B and a P/E ratio of 11.6. Today's range spans $48.73–$49.64, with shares opening at $49.17 and moving up $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 67/100.

Over the past year NVO has traded between $224.25 and $464.60 - the current price is -77.9% off the 52-week low and -89.3% from the high. 37 analysts cover the stock with a Hold consensus and a mean 12-month target of $47.95 (range $39.56–$63.00), implying downside of -3.1%.

Earnings revision cycles for mega-cap Healthcare stocks typically don't move in isolation - they attract analyst upgrades, price target increases, and incremental institutional allocation simultaneously. NVO's current bullish setup (82/100, BUY, sentiment bullish at 67/100, price $49.49 (near 52-week lows)) is the kind of profile that precedes or accompanies that revision cycle in names of this size (1419.18B market cap). (P/E: 11.6) Range: $224.25–$464.60.

For portfolio managers constructing Healthcare exposure, a mega-cap with a BUY signal and bullish news backdrop represents the kind of conviction-generating setup that justifies moving from benchmark weight to overweight. The 82/100 technical score at $49.49 (near 52-week lows) provides the entry discipline; the 1419.18B market cap provides the exit liquidity — a combination most position-sizing frameworks actively seek.

News Sentiment Analysis

Sentiment gathered from recent headlines

67/100

Strong NegativeNeutralStrong Positive

MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Novo Nordisk’s shares surged 11.2% over the past month, outpacing the S&P 500 and the large‑cap pharma sector. Zacks highlights that earnings estimate revisions are the primary driver behind the stock’s recent rally. The company’s strong performance suggests that analysts are optimistic about future earnings growth, which could sustain upward momentum. Traders should watch for any changes in analyst consensus and updates on the company’s product pipeline.

What did this article say?

Singapore regulators updated Wegovy’s label with STEP UP trial data, adding new efficacy evidence for non‑diabetic patients. The update has lifted investor focus, with a 19% 30‑day price gain, though long‑term shareholder returns remain negative. The move reinforces Novo Nordisk’s position in the obesity franchise and supports a valuation narrative that the stock remains undervalued.

What did this article say?

Novo Nordisk has revised the Wegovy label in Singapore to incorporate data from the STEP UP trial, potentially expanding the drug’s approved indications or dosing regimens. The update signals the company’s intent to align its product with emerging clinical evidence and may influence prescribing patterns in the Singapore market. The change could also affect future sales projections and regulatory discussions in the region.

What did this article say?

Novo Nordisk (NVO) secured a partnership with Vivani Medical to evaluate NPM-139, a semaglutide implant for chronic weight management, adding a new obesity drug delivery option to its portfolio. The deal comes amid recent share price gains, with a 30‑day return of 18.81% and a 90‑day return of 35.72%. While long‑term returns remain negative, the partnership may justify a higher valuation if the implant proves clinically successful. Investors should assess how the new data point fits into NVO’s broader obesity strategy and whether it can drive future revenue growth.

What did this article say?

Novo Nordisk (NVO) fell 1.51% to $48.89, outpacing the broader market’s 0.28% loss. The company’s upcoming earnings are expected to show a 15.46% decline in EPS to $0.82, while revenue is projected to drop 2.89% to $11.35 billion. Year‑to‑year guidance for the full year forecasts earnings of $3.38 per share and revenue of $45.3 billion, reflecting a 14.65% and 3.15% decline respectively. These negative outlooks may weigh on investor sentiment and could influence short‑term trading decisions.

What did this article say?

Deutsche Bank’s latest prescription data indicates a slowdown in the oral version of Novo Nordisk’s Wegovy weight‑loss drug, pushing shares down 2.5%. The analysis projects single‑digit downside for the Wegovy pill through 2026, while the injectable version and Rybelsus face double‑digit declines. Ozempic remains a bright spot with expected double‑digit upside. The slowdown threatens Novo’s growth trajectory as rivals accelerate their own oral weight‑loss offerings.

What did this article say?

UBS has reaffirmed an overweight rating on European pharmaceuticals, citing improved earnings revisions and low valuations. The bank highlights weight‑loss drugs, particularly the GLP‑1 class, as the near‑term catalyst, with Novo Nordisk’s Wegovy positioned as a leading theme. Medicare coverage for Wegovy is set to begin on July 1, offering a potential demand test as patients pay $50 monthly while the U.S. government covers the remainder. The shift away from AI toward pharma reflects a broader view of defensive quality and resilience in the current market environment.

What did this article say?

Novo Nordisk has entered a non‑exclusive agreement with Vivani Medical to evaluate NPM‑139, a subdermal semaglutide implant designed for chronic weight management. The partnership aims to address adherence and tolerability issues associated with weekly injectable GLP‑1 therapies. No financial terms or exclusivity clauses were disclosed, indicating a collaborative research focus. The implant leverages Vivani’s NanoPortal technology to deliver steady medication over extended periods.

What did this article say?

Novo Nordisk (NVO) and Vivani Medical are collaborating to evaluate a semaglutide implant using Vivani's NanoPortal platform. A Phase 1 clinical study has begun, while NVO is assessing the drug delivery format. The implant could provide an alternative to oral pills and injections for obesity treatment, expanding NVO's GLP‑1 obesity portfolio. Investors should watch the Phase 1 results and NVO's ongoing evaluation for potential impact on the company’s obesity pipeline.

What did this article say?

No summary available yet for this article.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

No summary available yet for this article.

NVO·Novo Nordisk A/S

EPS

Revenue

NVO Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More